Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices QBT Fatty Acid Uptake Assay Kits, GeneGo s MetaDrug v1.0 and MetaCore, Ibidi s micro-Slides, and Ambion s Silencer Labeled Control siRNAs

Premium

Molecular Devices said last week that it has launched QBT Fatty Acid Uptake Assay Kits. MDCC said it is the first single-step, homogenous, in vitro assay for fatty acid uptake for use in high-throughput screening and metabolic disease research. According to the company, it is similar to its FLIPR assay kits in that it does not require cell-washing steps.


GeneGo has launched MetaDrug v1.0, the company said last week. According to the company, MetaDrug is a systems-ADME/Tox platform that combines software for predicting metabolites and more than 40 ADME/Tox properties with visualization and analysis of toxicogenomics and metabolomics data. MetaDrug can be used as a stand-alone product, or together with MetaCore, GeneGo’s flagship analytical platform, it said.


Ibidi has launched micro-Slides, a product for cell culturing and high-resolution microscopy on a single slide. The high optical quality of the micro-Slides allows them to be used for cell-based assays in research and high-throughput applications, Ibidi said. The slides can be used for all fluorescence techniques, and in combination with phase-contrast, differential interference contrast, and confocal microscopy. In addition, the slides can handle cell or tissue samples in parallel in 18 wells, the company said.


Ambion recently introduced Silencer labeled control siRNAs. According to the company, the siRNAs are fluorescently labeled, allowing direct observation of their cellular uptake, distribution, and localization. The labeling allows researchers to monitor siRNA delivery by fluorescence microscopy, as opposed to unlabeled siRNAs that must be monitored by target gene knockdown. Additional details about the siRNAs can be found at http://www.ambion.com/catalog/CatNum.php?4620.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.